E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Epilepsy with partial seizures (including secondarily generalized seizures) |
|
E.1.1.1 | Medical condition in easily understood language |
Chronic disorder of brain function characterized by seizures |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy, safety and pharmacokinetics of gabapentin as adjunctive therapy in pediatric subjects with partial seizures (including secondarily generalized seizures) when other antiepileptics do not provide satisfactory effects.
To confirm that the upper limit of the 95 percent (%) confidence interval of R Ratio (mean) of the gabapentin group in this study will be below R Ratio (least squares mean) of the placebo group in overseas study. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age: 3 -15 years old at acquisition of informed consent
2. Sex: Male or female
3. Subjects seizures are classified as simple partial, complex partial or partial becoming secondarily generalized (defined according to the International League against Epilepsy).
4. Subjects who started being treated with antiepileptic drug at least 1 year ago, and who have not been able to achieve adequate seizure control with at least 2 different antiepileptic drugs despite having received each for at least 4 weeks.
5. Subjects receiving one, two, or three antiepileptic drugs at screening. However benzodiazepines which are administrated every day or alternate day are counted as one antiepileptic drug.
6. Subjects must have had a computed tomography (CT) scan or a Magnetic resonance imaging (MRI) within 2 years prior to screening.
7. Females of childbearing potential have a negative urine pregnancy test at screening.
8. Subjects and legal guardians must be thought to be compliant and able to follow the investigator’s instructions. They must be able to visit the clinic on schedule, be co-operative and reliable. They, or reliable observers, must be thought able to document the occurrence of seizures.
9. Subjects and /or legal guardians must give written informed consent prior to the start of the study. The acquisition of informed consent is made by Subjects as much as possible. |
|
E.4 | Principal exclusion criteria |
1. Subjects with seizures related to drugs, or acute medical illness.
2. Any subject with an Aspartate Aminotransferase (AST), Alanine transaminase (ALT), total bilirubin, Blood urea nitrogen (BUN) or creatinine above twice the upper limit of normal range within 6 months prior to screening (if data is available) and at screening.
3. Any subject with a white blood cell counts below 3000/ millimeter(mm)^3 or neutrophil counts below 1500/mm^3 within 6 months prior to screening (if data is available) and at screening.
4. Subjects who had taken other investigational drugs within the last 3 months prior to screening.
5. Subjects with a history of any serious medical or psychiatric disorder within 6 months prior to screening.
6. Subjects with a history of a structural Central Nervous system (CNS) lesion or an encephalopathy shown to be progressive.
7. Subjects with a structural lesion in the CNS or an encephalopathy shown to be progressive by CT scan or MRI within 2 years prior to screening.
8. Subjects who had had any Anti-epileptic drug (AED) withdrawn within 4 weeks prior to screening.
9. Subjects taking any non-AED medication that could alter the effectiveness of the subject’s medication response, seizure frequency or characteristics.
10. Any suject not reasonably expected to complete the trial.
11. Subjects with any other condition in which the investigator judge the subject unsuitable for participation in the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Response Ratio of Gabapentin in Japanese Paediatric Subjects With Partial Seizures |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
-Responder Rate
-Percent Change in Seizure Frequency (PCH) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 15 |